Literature DB >> 8190123

Effect of amino group modification of ovine luteinizing hormone (oLH) by N-succinimidyl 6-[3-(2-pyridyldithio)propionate]hexanoate, a long chain N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) on immunological and biological properties: a comparative study with SPDP modified oLH.

V Singh1, R Curtiss.   

Abstract

The epsilon-NH2 groups of ovine luteinizing hormone has been modified with the long chain N-succinimidyl-3-(2-pyridyl dithiopropionate (LC-SPDP). The LC-SPDP modification primarily occurs in -NH2 groups of the alpha-subunit. Although, the sequential modification of lysine residue in alpha-subunit led to progressive reduction in the receptor binding and immunological properties but the steroidogenic activity was relatively unaffected. The immunoreactivity and receptor binding properties of LC-SPDP modified oLH molecule were more affected comparative to SPDP modified derivatives. This suggested that the increase in hydrophobic carbon chain in LC-SPDP-oLH molecules resulted into the drastic inhibition in the immunological and biological properties. However, the steroidogenic potential of LC-SPDP/or SPDP-oLH derivative was comparable. The present study clearly demonstrate that a single -NH2 group modification with LC-SPDP would generate the site for the conjugation to the toxin/carrier proteins and the resultant oLH-S-S-toxin conjugate would retain significant immunological and biological properties of the hormone molecule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190123     DOI: 10.1007/bf01084271

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  27 in total

1.  Preparation of lutropin with acetyl or acetimidinyl substituents on the amino groups of the beta-subunit.

Authors:  W K Liu; D N Ward
Journal:  Biochim Biophys Acta       Date:  1975-10-20

2.  Hormonotoxins: synthesis, characterization and bioefficacy of some defined disulfide linked conjugates of ovine LH with a ribosome inactivating protein, gelonin.

Authors:  V Singh
Journal:  Indian J Exp Biol       Date:  1991-10       Impact factor: 0.818

3.  Role of arginine residues in ovine lutropin: reversible modification by 1,2-cyclohexanedione.

Authors:  M R Sairam
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

4.  Hormonotoxins: conjugation of human choriogonadotropin with the ribosome inactivating protein gelonin and comparison with a lutropin conjugate.

Authors:  V Singh; M R Sairam
Journal:  Mol Cell Endocrinol       Date:  1989-12       Impact factor: 4.102

5.  Enhancement of antigonadotropin response to the beta-subunit of ovine luteinizing hormone by carrier conjugation and combination with the beta-subunit of human chorionic gonadotropin.

Authors:  G P Talwar; O Singh; V Singh; D N Rao; N C Sharma; C Das; L V Rao
Journal:  Fertil Steril       Date:  1986-07       Impact factor: 7.329

6.  Immunospecificity and affinity studies on the monoclonal anti-gonadotropin releasing hormone (GnRH) antibodies: monoclonals produced by azotized GnRH preferentially recognise to native GnRH.

Authors:  V Singh
Journal:  Biochem Int       Date:  1987-07

7.  The role of the amino group in subunit association and receptor site interaction for ovine luteinizing hormone as studied by acylation.

Authors:  W K Liu; K P Yang; Y Nakagawa; D N Ward
Journal:  J Biol Chem       Date:  1974-09-10       Impact factor: 5.157

Review 8.  Glycoprotein hormones: structure and function.

Authors:  J G Pierce; T F Parsons
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

9.  Effects of thiolation of amino groups of ovine lutropin on immunoreactivity, receptor binding and bioactivity.

Authors:  V Singh; M R Sairam
Journal:  Mol Cell Endocrinol       Date:  1989-05       Impact factor: 4.102

10.  Structural requirement for the recognition of luteinizing hormone releasing hormone (LHRH) by monoclonal and conventional anti-LHRH antibodies.

Authors:  V Singh
Journal:  Biochem Cell Biol       Date:  1986-12       Impact factor: 3.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.